Accessibility Menu
Genetic Signatures logo

Genetic Signatures(ASX) GSS

Market CapA$18.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-82%
5 Year-95%
1 Year-71%
1 Month+40%
A$0.09
+7.41%
+0.01Today
Genetic Signatures last closing stock price
MetricPriceDate
Last closeAUD 0.082026-09-07
Genetic Signatures stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.74%AUD 0.102026-08-31
1 month+39.66%AUD 0.062026-08-07
3 month+14.08%AUD 0.072026-06-09
Year to date-67.6%AUD 0.252025-12-31
1 year-71.07%AUD 0.282025-09-05
3 year-84.86%AUD 0.542023-09-07
5 year-94.77%AUD 1.552021-09-08
Since inception-81.64%AUD 0.472015-03-31

Genetic Signatures Financials at a Glance

Market Cap

A$18.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$30.35M

Net Income (TTM)

-A$34.11M

EPS (TTM)

-A$0.06

P/E Ratio

-1.31

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.09

Volume

69,675

Open

A$0.09

Previous Close

A$0.09

Daily Range

A$0.08 - A$0.09

52-Week Range

A$0.05 - A$0.43

Estimated Earnings Date

Feb 16, 2027

GSS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genetic Signatures

Genetic Signatures Limited is a molecular diagnostics company specializing in real-time Polymerase Chain Reaction (PCR)-based products for infectious disease identification. The company operates globally, providing innovative solutions to hospitals and laboratories through its proprietary MDx 3Base platform technology.

Products and Services
  • EasyScreen brand detection kits for various infectious diseases
  • Comprehensive screenings for gastrointestinal, respiratory, and tropical diseases
  • Proprietary MDx 3Base platform technology for enhanced diagnostic accuracy
Growth Outlook
  • Expansion into new markets across the Asia Pacific and Americas
  • Increased demand for diagnostic solutions post-pandemic
  • Investment in R&D to enhance product offerings and capabilities
Financial Highlights
  • Recent quarterly revenue of AUD 5.77 million, showing a strategic focus on growth
  • Cash and short-term investments totaling AUD 22.1 million, providing operational flexibility
  • Current ratio of 13.1, indicating strong liquidity and financial health
Genetic Signatures Limited is positioned in the healthcare sector, specifically within medical diagnostics and research. The company has a diverse product portfolio that addresses various infectious diseases, which is increasingly relevant in today's health landscape. The growth outlook is promising, driven by expanding market opportunities and a focus on innovation. Financially, the company maintains a solid liquidity position, which is crucial for sustaining operations and funding future growth initiatives. The recent revenue figures reflect ongoing efforts to enhance market presence and operational efficiency. Overall, Genetic Signatures Limited presents a compelling opportunity for investors interested in the healthcare diagnostics sector.
AI Generated • Aug 26, 2026

Industry

Life Sciences Tools and Services

CEO

Maria Julianna Halasz, MBA

Headquarters

Newtown, NSW 2042, AU

GSS Financials

Key Financial Metrics (TTM)

Gross Margin

-88.02%

Operating Margin

-122.76%

Net Income Margin

-96.91%

Return on Equity

-35.10%

Return on Capital

-49.24%

Return on Assets

-36.42%

Earnings Yield

-76.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$18.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

227.14M

Volume

69.67K

Avg. Volume

596.71K

Financials (TTM)

Gross Profit

-A$15.11M

Operating Income

-A$33.64M

EBITDA

-A$31.55M

Operating Cash Flow

-A$20.06M

Capital Expenditure

-A$1.70M

Free Cash Flow

-A$21.76M

Cash & ST Invst.

A$22.10M

Total Debt

A$310.00K

Genetic Signatures Performance Analysis

Genetic Signatures annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 16,939,000-52.2%
20242024-06-30AUD 9,766,000-42.3%
20252025-06-30AUD 15,900,00062.8%
20262026-06-30AUD 14,453,000-9.1%
Genetic Signatures sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3137.9%
Q42025-06-30-12.9%
Q22025-12-3117.3%
Q42026-06-30-33.5%
Genetic Signatures annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.10N/A
20242024-06-30AUD -0.1113.0%
20252025-06-30AUD -0.09-17.9%
20262026-06-30AUD -0.06-30.4%
Genetic Signatures sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-95.5%
Q42025-06-3068.6%
Q22025-12-31-29.6%
Q42026-06-30-20.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$5.77M

-6.3%

Gross Profit

-A$6.11M

+13.6%

Gross Margin

-1.06%

N/A

Market Cap

A$18.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$157.25K

N/A

Employees

117

N/A

Net Income

-A$7.64M

-3.4%

EBITDA

-A$7.90M

+9.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$22.10M

-39.1%

Total Debt

A$310.00K

-74.6%

Accounts Receivable

A$7.07M

+56.2%

Inventory

A$6.21M

-7.7%

Long Term Debt

A$4.00K

-99.5%

Short Term Debt

A$306.00K

-21.9%

Return on Assets

-36.42%

N/A

Return on Invested Capital

-49.62%

N/A

Free Cash Flow

-A$7.87M

+14.6%

Operating Cash Flow

-A$7.42M

+3.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MX1.AXMicro-X Limited
A$0.02-4.76%
IPD.AXImpediMed Limited
A$0.01+0.00%
BMT.AXBeamtree Holdings Limited
A$0.11-4.35%
CYP.AXCynata Therapeutics Limited
A$0.01+4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About GSS

What is the current price of Genetic Signatures?

Genetic Signatures is trading at A$0.09 per share.

What is the 52-week range for Genetic Signatures?

Over the past 52 weeks, Genetic Signatures has traded between A$0.05 and A$0.43.

How much debt does Genetic Signatures have?

As of the most recent reporting period, Genetic Signatures reported total debt of A$310.00K.

How much cash does Genetic Signatures have on hand?

Genetic Signatures reported A$9.07M in cash and cash equivalents in its most recent financial results.

What is Genetic Signatures’s dividend yield?

Genetic Signatures does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.